Alpha-1 Antitrypsin Deficiency
Research activity is centered on severe alpha-1 antitrypsin deficiency (AATD), with attention to the clinical management of this inherited protein deficiency disorder and its impact on long-term health.
- Severe AATD
- Inherited respiratory and hepatic disease
- Protein replacement therapy
The sponsor’s funded research in this area reflects interest in treatment approaches for patients living with advanced deficiency-related disease.
Self-Administration and Infusion Care
Clinical interest includes self-infusion therapy for protein replacement treatment, with emphasis on patient use of established infusion-based care in a home or ambulatory setting.
- Self-infusion therapy
- Infusion-based treatment
- Patient-managed care
This area highlights practical therapeutic delivery for individuals requiring ongoing replacement therapy.
Clinical Safety
Funded research also focuses on safety evaluation and monitoring of treatment tolerability in patients receiving therapy for severe AATD.
- Safety assessment
- Treatment tolerability
- Clinical monitoring
These interests support the assessment of how therapy is used in routine patient care.
Clinical Parameter Assessment
Research activity includes evaluation of clinical parameters relevant to disease management in alpha-1 antitrypsin deficiency, with focus on patient status during therapy.
- Clinical parameters
- Disease management
- Therapeutic response
The sponsor’s interest lies in understanding treatment use alongside routine clinical observation in this rare disorder.
